Form 4: Jazz Pharmaceuticals CEO Sells Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
Jazz Pharmaceuticals plc's Chairman and CEO, Bruce C. Cozadd, reported the sale of 1,000 ordinary shares through a pre-arranged Rule 10b5-1 trading plan.
Summary
- Bruce C. Cozadd, Chairman & CEO and Director of Jazz Pharmaceuticals plc, reported transactions involving the sale of ordinary shares.
- On July 1, 2025, 500 ordinary shares were sold at a price of $105.26 per share.
- On July 1, 2025, an additional 500 ordinary shares were sold at a price of $110 per share.
- These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Cozadd.
- Following these reported transactions, Mr. Cozadd beneficially owns 436,973 ordinary shares directly.
Sentiment
Score: 5
Explanation: The document reports routine insider share sales executed under a pre-arranged Rule 10b5-1 trading plan, which is a neutral event as it indicates the transaction was not based on new, non-public information.
Stakeholder Impact
- Shareholders: The sale of shares by the Chairman & CEO, even under a Rule 10b5-1 plan, may be viewed by some shareholders as a reduction in direct alignment with the company's stock performance, though it is a common practice for personal financial planning.
Key Dates
| Date | Description |
|---|---|
| 07/01/2025 | Date of reported share transactions by Bruce C. Cozadd. |
| 07/03/2025 | Date the Form 4 was signed and filed. |
Keywords
Jazz Pharmaceuticals, JAZZ, Bruce C. Cozadd, Form 4, Insider Trading, Share Sale, 10b5-1 Plan, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.